bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse

Similar Items

• r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement
  od: Beckmann, Joshua S., i dr.
  Izdano: (2015)
• Repeated Nicotine Administration Robustly Increases bPiDDB Inhibitory Potency at α6β2-containing Nicotinic Receptors Mediating Nicotine-evoked Dopamine Release
  od: Smith, Andrew M., i dr.
  Izdano: (2010)
• Nicotinic Receptor Antagonists as Treatments for Nicotine Abuse
  od: Crooks, Peter A., i dr.
  Izdano: (2014)
• N,N′-Alkane-diyl-bis-3-picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-induced Dopamine Release and Hyperactivity
  od: Dwoskin, Linda P., i dr.
  Izdano: (2008)
• Novel bis-, tris-, and tetrakis-tertiary amino analogues as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release
  od: Zhang, Zhenfa, i dr.
  Izdano: (2010)